Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • Soligenix axes lymphoma program after phase 3 setback, mulls M&A options

Soligenix axes lymphoma program after phase 3 setback, mulls M&A options

  • June 15, 2026

Soligenix has scrapped its cutaneous T-cell lymphoma program in the wake of a phase 3 setback, leaving the biotech focused on another rare disease prospect and considering strategic alternatives.

Leave A Comment

Fields (*) Mark are Required